Seres Therapeutics, Inc. (NASDAQ:MCRB) – Investment analysts at Leerink Swann increased their Q3 2017 earnings estimates for shares of Seres Therapeutics in a research report issued on Thursday. Leerink Swann analyst J. Schwartz now anticipates that the biotechnology company will post earnings of ($0.23) per share for the quarter, up from their prior forecast of ($0.73). Leerink Swann also issued estimates for Seres Therapeutics’ Q4 2017 earnings at ($0.74) EPS, FY2017 earnings at ($2.30) EPS, FY2018 earnings at ($2.49) EPS and FY2019 earnings at ($2.24) EPS.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.59) by $0.10. The business had revenue of $3 million during the quarter, compared to the consensus estimate of $3 million. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 73.45%. The company’s revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.70) EPS.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/08/07/leerink-swann-research-analysts-increase-earnings-estimates-for-seres-therapeutics-inc-nasdaqmcrb.html.

Several other equities research analysts have also weighed in on MCRB. Canaccord Genuity set a $20.00 price objective on Seres Therapeutics and gave the stock a “buy” rating in a report on Thursday, May 4th. Cantor Fitzgerald set a $16.00 price objective on Seres Therapeutics and gave the stock a “buy” rating in a report on Thursday, May 4th. Cowen and Company reissued a “buy” rating on shares of Seres Therapeutics in a report on Friday, May 19th. Zacks Investment Research raised Seres Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Wednesday, July 5th. Finally, BidaskClub raised Seres Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $16.17.

Shares of Seres Therapeutics (NASDAQ MCRB) opened at 13.69 on Monday. The company’s market cap is $552.94 million. Seres Therapeutics has a 12 month low of $8.85 and a 12 month high of $15.09. The stock has a 50 day moving average of $11.94 and a 200-day moving average of $10.51.

A number of hedge funds and other institutional investors have recently bought and sold shares of MCRB. State Street Corp raised its position in Seres Therapeutics by 6.4% in the fourth quarter. State Street Corp now owns 275,970 shares of the biotechnology company’s stock worth $2,733,000 after buying an additional 16,671 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Seres Therapeutics by 35.0% in the fourth quarter. Renaissance Technologies LLC now owns 400,300 shares of the biotechnology company’s stock worth $3,963,000 after buying an additional 103,800 shares during the period. Teachers Advisors LLC increased its stake in shares of Seres Therapeutics by 43.5% in the fourth quarter. Teachers Advisors LLC now owns 41,101 shares of the biotechnology company’s stock worth $407,000 after buying an additional 12,462 shares during the period. Bank of Montreal Can increased its stake in shares of Seres Therapeutics by 33.7% in the first quarter. Bank of Montreal Can now owns 19,144 shares of the biotechnology company’s stock worth $216,000 after buying an additional 4,829 shares during the period. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Seres Therapeutics during the first quarter worth about $136,000. 75.52% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.